Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M

BIODESIX INC

Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).
Net loss Q4 $20.3M, FY2022 $65.4M; includes $7.0M loss on debt extinguishment/modification.
Cash and equivalents $43.1M at Dec 31, 2022; raised $65.7M net from debt/equity in Q4.
2023 total revenue guidance $52-55M, representing 36-44% growth over 2022 total revenue.
Biopharma services revenue $3.7M in FY2022 (-34% YoY); highest dollars under contract entering 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

BIODESIX INC reported fourth quarter and fiscal 2022 results: revenue $9.6 million and $38.2 million, net income Net loss of $20.3 million and $65.4 million. Guidance reaffirmed.

Period: fourth quarter and fiscal 2022
Revenue: $9.6 million and $38.2 million
Net income: Net loss of $20.3 million and $65.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.67

BIODESIX INC updated its the fourth quarter and year ended December 31, 2022 guidance (reaffirmed).

Period: the fourth quarter and year ended December 31, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 6, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0000950170-23-006084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.